ImmunityBio, Inc.
IBRX· Nasdaq· Biological Products, (No Diagnostic Substances)
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- -272.6%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +184.8%
We record prices for the companies we cover; IBRX is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 919.9M
- Revenue
- $113.3M
- Free cash flow
- -$308.8M
- Owner earnings
- -$345.6M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -226.0%
- Net
- -310.2%
- Free cash flow
- -272.6%
- Owner earnings
- -305.1%
- Stock pay
- 32.5%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- –
- ROE, 5 yr avg
- –
Growth (CAGR)
- Revenue, 3 yr
- 678.6%
- Revenue, 5 yr
- 184.8%
- Revenue, 9 yr
- 139.3%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $242.8M
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 19.5%
Financials: ten years from the 10-Ks
Revenue
$113.3M
+139.3% a year over 9 years
FY2016FY2025
Margins
Operating-226.0%Net-310.2%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow-$308.8MOwner earnings-$345.6M
FY2025
FY2016FY2025
Diluted shares
919.9M
+151.1% over 9 years, net dilution
FY2016FY2025
Net cash
–
$149.8M more cash than debt
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $44.0K | $45.0K | $47.0K | $2.2M | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $113.3M |
| Revenue growth | -81.4% | 2.3% | 4.4% | 4585.1% | -72.5% | 54.4% | -74.3% | 159.2% | 2270.6% | 668.3% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | -282954.5% | -220266.7% | -209338.3% | -7095.9% | -36509.1% | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Net income | -$120.8M | -$96.4M | -$96.2M | -$157.8M | -$221.9M | -$346.8M | -$416.6M | -$583.2M | -$413.6M | -$351.4M |
| Net margin | -274565.9% | -214273.3% | -204736.2% | -7165.2% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
| Diluted EPS | – | – | – | $-0.43 | $-0.59 | $-0.89 | $-1.04 | $-1.15 | $-0.62 | $-0.38 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | -$38.6M | -$48.8M | -$63.4M | -$152.1M | -$171.7M | -$274.4M | -$337.5M | -$366.8M | -$391.2M | -$304.9M |
| Capital expenditure | $6.6M | $34.8M | $13.1M | $4.3M | $1.7M | $33.6M | $78.2M | $30.6M | $6.9M | $3.8M |
| Free cash flow | -$45.2M | -$83.6M | -$76.5M | -$156.4M | -$173.4M | -$308.0M | -$415.7M | -$397.3M | -$398.1M | -$308.8M |
| Stock-based compensation | $73.9M | $37.0M | $23.4M | $3.4M | $2.2M | $57.2M | $40.2M | $49.2M | $34.4M | $36.8M |
| Owner earnings? | -$119.0M | -$120.6M | -$99.9M | -$159.8M | -$175.6M | -$365.2M | -$455.9M | -$446.5M | -$432.6M | -$345.6M |
| Free cash flow per share | – | – | – | $-0.43 | $-0.46 | $-0.79 | $-1.04 | $-0.78 | $-0.57 | $-0.34 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | $15.8M | $15.2M | $228.0K | $2.5M | $0 | $0 | – | – | – | – |
| Diluted shares | – | – | – | 366.3M | 377.1M | 389.2M | 399.9M | 508.6M | 700.4M | 919.9M |
| Share count change? | – | – | – | – | 2.9% | 3.2% | 2.7% | 27.2% | 37.7% | 31.3% |
| Balance sheet | ||||||||||
| Cash and equivalents | $8.1M | $23.9M | $16.8M | $75.8M | $34.9M | $181.1M | $104.6M | $265.5M | $143.4M | $88.3M |
| Short-term investments | $190.8M | $104.3M | $57.3M | $36.1M | $61.1M | $136.0M | $2.5M | $1.0M | $6.4M | $154.5M |
| Total debt | – | – | – | – | – | – | $241.3M | $577.0M | $0 | – |
| Net debt | – | – | – | – | – | – | $134.1M | $310.5M | -$149.8M | – |
| Shareholders' equity | $293.4M | $218.8M | $146.0M | $120.7M | -$119.8M | -$242.2M | -$447.3M | -$587.0M | -$489.1M | -$500.5M |
Latest filings
| 2026-08-04 | 10-Q | Quarterly report |
| 2026-08-04 | 8-K | Earnings release |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Earnings release |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-09 | 8-K | Earnings release |
| 2026-02-23 | 10-K | Annual report |
| 2026-02-23 | 8-K | Earnings release |
| 2026-01-15 | 8-K | Earnings release |
| 2025-11-05 | 10-Q | Quarterly report |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
